483
Ascent Pharmaceuticals IncAscent Pharmaceuticals Inc – FDA 483, Sep 15, 2022
Record Details
An FDA inspection of Ascent Pharmaceuticals Inc's corporate headquarters in Central Islip, NY, revealed a significant lapse in their Risk Evaluation and Mitigation Strategy (REMS) program. The firm failed to maintain its approved REMS Implementation System by not providing required REMS-specific links on its product website to the official REMS Program website. This indicates a failure to comply with post-market requirements for their opioid analgesic products.
View Company Profile
ID · 2e23b981-2208-442a-b00c-5dea4a7b4772
Other documents for Ascent Pharmaceuticals Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.